Dose increase augments the response rate to inteferon-α in chronic hepatitis C

Ferenci, Péter; Stauber, R.E.; Propst, A; Fiedler, Roman; Gschwantler, Michael; Schütze, K; Judmaier, G; Krejs, G J; Gangl, Alfred

doi:10.1016/0016-5085(95)28557-1

Gastroenterology

1995

DOI: 10.1016/0016-5085(95)28557-1

|View full text |Cite

Dose increase augments the response rate to inteferon-α in chronic hepatitis C

Péter Ferenci¹,

R.E. Stauber²,

A Propst³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1996

1997

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

High-dose interferon-α2b for re-treatment of nonresponders or relapsing patients with chronic hepatitis C

Bonkovsky¹,

Clifford²,

Smith³

et al. 1996

Digest Dis Sci

View full text Add to dashboard Cite

Relatively few patients with chronic hepatitis C treated with standard doses of interferon-alpha 2b (3 million units per week for 24 weeks) have a sustained response. Our aim was to evaluate whether higher doses of interferon would improve this rate of response. Twenty-four patients with chronic hepatitis C who had failed to respond to (N = 21) or had relapsed after (N = 3) an initial course of standard interferon therapy were randomized to 15 million units (N = 13) or 22.5-30 million units per week (N = 11) for 24 weeks. Five of 13 subjects given 15 million units per week and 3/11 of subjects given 22.5-30 million units per week had complete normalization of serum alanine aminotransferase levels during therapy. Five patients (24% who had not responded to standard interferon had a complete response to high-dose interferon during therapy. Only one patient had a sustained response, with normal serum alanine aminotransferase 24 weeks after stopping interferon. Six patients were withdrawn before completing treatment, five in the 22.5-30 million unit per week group. We conclude that higher doses of interferon ameliorate the severity of hepatitis in patients who failed to respond to or relapsed after standard interferon therapy, but are unlikely to produce a sustained response. High-dose therapy is associated with an increase in side effects.

show abstract

High-dose interferon-α2b for re-treatment of nonresponders or relapsing patients with chronic hepatitis C

Bonkovsky¹,

Clifford²,

Smith³

et al. 1996

Digest Dis Sci

View full text Add to dashboard Cite

show abstract

Treatment of HCV

Schiff

Tagle

1997

Clinics in Liver Disease

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Dose increase augments the response rate to inteferon-α in chronic hepatitis C

Cited by 2 publications

References 0 publications

High-dose interferon-α2b for re-treatment of nonresponders or relapsing patients with chronic hepatitis C

High-dose interferon-α2b for re-treatment of nonresponders or relapsing patients with chronic hepatitis C

Treatment of HCV

Contact Info

Product

Resources

About